Revenue Guidance

Business

Northland Cuts Bitdeer Price Target to $25 After December Update, Maintains Bullish Stance

Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.

Jan 30, 2026

Business

Maxim Group Reiterates Bullish Stance on Strive (ASST), Sees 50% Upside to $1.50 Target

Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Beyond the Roth Hype: Why Traditional Retirement Accounts May Be the Smarter Tax Move for Many

While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.

Jan 30, 2026

Business

Standex Delivers Strong Q2 Growth, Fueled by Grid and New Products; Reiterates FY2026 Outlook

Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.

Jan 30, 2026

Business

Standex Posts Record Margins, Outlines Expansion Plans Amid Tariff Headwinds

Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.

Jan 30, 2026

Business

S&P Global and Goldman Sachs Boost Shareholder Returns with Latest Dividend Hikes

Two financial sector giants, S&P Global and Goldman Sachs, have announced increased quarterly payouts, signaling confidence in their financial health and future prospects amid a dynamic market environment.

Jan 30, 2026

Business

OpenAI's Reported 2026 IPO: A High-Stakes Test for the AI Investment Frenzy

Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.

Jan 30, 2026

Business

Cushman & Wakefield's Rally Faces Scrutiny: Is the Commercial Real Estate Giant's Run Sustainable?

Shares of Cushman & Wakefield have surged 35.8% in six months, dramatically outpacing the broader market. While strong quarterly results fueled the climb, a deeper look at the firm's long-term financial health reveals potential headwinds that could give investors pause.

Jan 30, 2026

Business

Bloomin' Brands Faces Headwinds: Debt, Stagnant Sales Cloud Outlook

Shares of restaurant operator Bloomin' Brands have tumbled over 35% in six months, raising questions about its financial health and growth trajectory as analysts flag significant risks.

Jan 30, 2026

Business

Darling Ingredients' Rally Raises Eyebrows: Analysts Flag Concerns, Suggest Alternative Play

Despite a 39% surge in six months, Darling Ingredients faces scrutiny over its long-term sales decline, margin pressures, and falling profitability. Analysts point investors toward more resilient sectors.

Jan 30, 2026

Business

Walker & Dunlop's Slide: Three Red Flags for Investors and a Safer Alternative

While the S&P 500 has climbed, Walker & Dunlop shares have tumbled over 14% in six months. We analyze the underlying weaknesses in its financials and highlight a more compelling opportunity for value-focused portfolios.

Jan 30, 2026

Business

Standex Bolsters Grid Tech Portfolio with $462M Amran/Narayan Acquisition Amid Record Margins

Standex International reported resilient Q1 2025 earnings with record gross margins above 40%, while announcing a transformative $462 million acquisition of Amran/Narayan Group, a leader in instrument transformers, aiming to double its exposure to fast-growing electrical infrastructure markets.

Jan 30, 2026

Business

Lazard Beats Estimates on Strong Advisory, Asset Management Performance

Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.

Jan 30, 2026

Business

Navigating the Giants: One Large-Cap Stock with Room to Run, and Two Facing Headwinds

While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.

Jan 30, 2026

Business

Wall Street's Bold Bets: One Stock Poised to Shine, Two Facing Headwinds

Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.

Jan 30, 2026

Business

Mixed Fortunes for Banking Giants: Citigroup Lags as Peers Navigate Q4 Headwinds

The fourth-quarter earnings season for diversified banks revealed a tale of divergence. While PNC Financial surprised to the upside, industry titan Citigroup fell short of expectations, highlighting the uneven pressures facing the sector.

Jan 30, 2026

Business

Guggenheim Boosts Bruker Price Target to $58, Citing Strong Diagnostics Outlook

Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.

Jan 30, 2026

Business

Hedge Funds Bet Big on Insulet's Omnipod: Analysts See Over 40% Upside for Diabetes Tech Leader

Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.

Jan 30, 2026

Business

Boston Scientific Gains Analyst Favor Following Penumbra Acquisition, Price Target Raised

Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.

Jan 30, 2026